This study was a retrospective consecutive case series of patients diagnosed with treatment-naïve unilateral CRVO between January 2010 and September 2017 at the Hangil Eye Hospital. The inclusion criteria for this study were as follows: (1) symptomatic CRVO in which retinal hemorrhage and retinal edema involved the macula, (2) foveal thickness greater than 300 μm as measured by OCT at initial visits, and (3) macular edema treated with intravitreal bevacizumab. An intravitreal injection of bevacizumab was administered in the same manner as reported previously28 (link). All patients were treated using a pro-re-nata regimen. The diagnosis of CRVO was based on the findings from fundus examination and fluorescein angiography. CRVO with a non-perfusion area larger than 10 disc areas on fluorescein angiography was defined as ischemic CRVO. Visual acuity improvement of 2 lines or more in the CRVO eyes following treatment was defined as a functional responder.
The exclusion criteria of the study included patients with any coexisting ocular diseases, such as age-related macular degeneration, diabetic retinopathy, and uveitis, as well as eyes that had received focal/grid laser photocoagulation, pan-retinal photocoagulation, prior intravitreal injections (e.g., intravitreal corticosteroids, intravitreal anti-VEGF agents), or prior ocular surgery (except cataract surgery). Patients were also excluded if they had refractive disorders greater than ± 3D.
Patient charts were reviewed for the following data: age, sex, medical history (hypertension and diabetes mellitus), best-corrected visual acuity (BCVA), axial length (measured with the IOL master; Carl Zeiss Meditec, Dublin, California, USA), anti-VEGF injection dates, and number of intravitreal injections. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR). The BCVA, IOP, and SFCT were compared between CRVO eyes and fellow eyes at each follow-up visit.
The exclusion criteria of the study included patients with any coexisting ocular diseases, such as age-related macular degeneration, diabetic retinopathy, and uveitis, as well as eyes that had received focal/grid laser photocoagulation, pan-retinal photocoagulation, prior intravitreal injections (e.g., intravitreal corticosteroids, intravitreal anti-VEGF agents), or prior ocular surgery (except cataract surgery). Patients were also excluded if they had refractive disorders greater than ± 3D.
Patient charts were reviewed for the following data: age, sex, medical history (hypertension and diabetes mellitus), best-corrected visual acuity (BCVA), axial length (measured with the IOL master; Carl Zeiss Meditec, Dublin, California, USA), anti-VEGF injection dates, and number of intravitreal injections. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR). The BCVA, IOP, and SFCT were compared between CRVO eyes and fellow eyes at each follow-up visit.
Free full text: Click here
